Background: Neurogenic detrusor overactivity in the bladder frequently results in urinary incontinence that impairs quality of life.
Objective:To assess the effects of onabotulinumtoxinA (BOTOX(®), Allergan, Inc.) on urinary incontinence in people with detrusor bladder problems.
Trial: This multicentre, randomised, double-blind, placebo-controlled study enrolled patients with multiple sclerosis (number of people n=154) or spinal cord injury (n=121) with detrusor bladder problems of more than 14 incontience episodes a week. Patients received 30 intradetrusor injections of onabotulinumtoxinA 200 Units (n=92), 300 Units (n=91), or placebo (n=92),
Conclusions: OnabotulinumtoxinA significantly reduced urinary incontinence and improved quality of Life MSers and people with spinal cord injury with detrusor muscle over activity. Both Doses were well tolerated (http://www.clinicaltrials.gov; NCT00461292).